Biotage AB and McMaster University Sign Agreement to Develop new Chemistry Platform
News Feb 26, 2007
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform to speed the production of molecular imaging and therapy agents.
As part of the agreement, Biotage will provide funding and instruments, including an Initiator microwave synthesizer, SP4 flash purification system, and V10 Evaporator. These automated instruments work together to streamline workflow and speed production.
The McMaster Institute of Applied Radiation Sciences (McIARS) will apply funding and equipment to speed the development of molecular imaging agents for PET and SPECT and radiotherapy agents for treatment applications.
According to Biotage, it is the only company that offers solutions for synthesis, purification and evaporation, providing instruments and consumables for these key development steps.
This partnership brings together synthesis and purification tools with radiopharmaceutical research which spans basic science to the development and testing of imaging and therapy agents. The new platform technologies will facilitate the process of producing tracers and therapeutics and it will be particularly useful for developing radiolabeled analogues of new drug candidates.
The latter aim is particularly important as imaging is playing an increasingly important role in early clinical trials, Dr. John F. Valliant, Associate Professor of Chemistry and Medical Physics, and Acting Director of McIARS stated.
Kelvin Hammond, Vice President of Business Development remarked, Molecular imaging will play a significant role in the future of drug discovery by enabling biodistribution and pharmacokinetic data to be acquired early on in the drug discovery process. This will enable companies to weed out compounds that are likely to fail before they enter larger and more expensive human clinical trials.
In a new study published in Cell Stem Cell, a team of researchers have demonstrated, using fat cells derived from human stem cells, that individual genetic variation can be used to predict whether the TZD rosiglitazone will produce the unwanted side effect of increasing cholesterol levels in certain individuals.READ MORE